A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.
about
Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A miceTreatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXAcquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.When should prophylaxis therapy in inhibitor patients be considered?Pharmacotherapy of haemophilia A.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO.Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors.On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey.How I treat inhibitors in haemophilia.Guidelines for the management of hemophilia.Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
P2860
Q30481282-45C4A542-1B4C-4BAD-9699-2B276441E37CQ33608230-07CE39D7-3208-4E35-AF23-C3A69D5CF830Q36187384-80B2FDAC-7CF5-4771-9F4D-8EC978426C78Q36945945-D8B8551D-203C-4FAD-9CE8-3F36AAE53987Q36981731-79352E9B-8132-44FC-947A-E303B4D6AD15Q37169669-9751FFC0-2E73-4D5B-B9EF-89247AD45FE6Q37610501-3B75EFC5-6F1D-4EB7-8D46-1C4C89AAD14CQ37842692-02029E2E-8083-46E3-BE10-35C812253B02Q37854874-01A7B3DC-7D23-40AD-92E4-321BE18BF60DQ37891089-D5CF2048-026D-48D6-91A6-E5E66CFE1288Q37927122-7E8A97C6-3B4D-440B-BFC5-217C748F70D9Q38060224-5ACD5EDA-B1ED-4CFF-B58D-436FE7CB6596Q38182105-A08734FF-D0CB-45FC-9314-A8F19EBD0BB7Q41210614-EB85D2EC-A782-4C21-BAEC-96BAC99226DBQ42776949-FCCE0286-298C-44C6-94BC-8AC5E60E2EBEQ44100628-60C7A270-341B-4D56-BBD5-A7149C358FEAQ44211358-ADBC3D27-BE37-4324-8B57-5F9987998ED3Q45838031-9F4E3A04-38AF-4686-930F-A55365087633Q45855511-1F032538-DAA3-4449-9D0D-535BFBF9AAFEQ45859196-3731C165-E2D5-4A34-92B6-A0461C5AC69BQ45862378-3D892ED3-26BE-4999-8068-4517461A020CQ45867938-B164A5AC-84E7-4C23-A36F-2EE1C8AD01CDQ45869629-B11AD468-9404-4BA6-A30C-6CB3F0BD9FF5Q45871901-A4C9570C-4ED7-44C7-838C-939E67DBBAF2Q45875224-68547E48-B996-413F-94E2-A03B01EF785AQ45879927-72678DE2-0D4B-48C6-98DC-D2B42F280327Q45880345-3E45F602-728D-44FD-870C-3CCB1581C4C9Q45887517-2BF3BF81-3774-4274-BE1F-3AEDC50CBE30
P2860
A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A systematic approach to contr ...... a A and high-titre inhibitors.
@en
A systematic approach to contr ...... a A and high-titre inhibitors.
@nl
type
label
A systematic approach to contr ...... a A and high-titre inhibitors.
@en
A systematic approach to contr ...... a A and high-titre inhibitors.
@nl
prefLabel
A systematic approach to contr ...... a A and high-titre inhibitors.
@en
A systematic approach to contr ...... a A and high-titre inhibitors.
@nl
P2093
P2860
P1433
P1476
A systematic approach to contr ...... ia A and high-titre inhibitors
@en
P2093
Berntorp E
Ewenstein B
Gomperts E
Goudemand J
Gringeri A
Leissinger C
P2860
P304
P356
10.1111/J.1365-2516.2007.01449.X
P577
2007-05-01T00:00:00Z